Eloralintide
NCT06230523
Eli Lilly · Phase 2 · Completed · Enrollment 263
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo | Obesity, no T2D | n/r | 48 | Efficacy | -0.4% at week 48 |
| 1 mg Eloralintide | Obesity, no T2D | 1 mg | 48 | Efficacy | -9% at week 48 |
| 3 mg Eloralintide | Obesity, no T2D | 3 mg | 48 | Efficacy | -12% at week 48 |
| 6 mg Eloralintide | Obesity, no T2D | 6 mg | 48 | Efficacy | -18% at week 48 |
| 9 mg Eloralintide | Obesity, no T2D | 9 mg | 48 | Efficacy | -20% at week 48 |
| 6/9 mg Eloralintide | Obesity, no T2D | 6/9 mg | 48 | Efficacy | n/r |
| 3/6/9 mg Eloralintide | Obesity, no T2D | 3/6/9 mg | 48 | Efficacy | n/r |